Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The investigators want to learn about treating relapsed/refractory lymphoblastic leukemia and
lymphoma with a drug called sirolimus. The investigators are using sirolimus along with other
cancer drugs that are often given to patients with relapsed leukemia and lymphoma.
The main purpose of this study is to determine if sirolimus can be given safely in
combination with standard drugs used to treat relapsed lymphoblastic leukemia/lymphoma.